Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Avastin | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Pharmaceuticals